Canadian Cancer Trials Group Bulletins

Trial Management Group


Two Other Recent Publications

Canadian Cancer Trials Group PA.3 -- A Randomized Placebo Controlled Study of OSI-774 Plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer (ONLINE). Cancer 2010.

http://onlinelibrary.wiley.com/doi/10.1002/cncr.25393/abstract

__________________________________________


Miller NA, Chapman J-AW, Qian J, Christens-Barry WA, Fu Y, Yuan Y, Lickley LA, Axelrod DE. Heterogeneity between ducts of the same nuclear grade involved by duct carcinoma in situ (DCIS) of the breast. Cancer Informatics 9: 216, 2010.

http://www.la-press.com/heterogeneity-between-ducts-of-the-same-nuclear-grade-involved-by-article-a2250